Single-use canister-free negative pressure wound therapy system engineered for canine and equine distal-limb wounds — business case

Intended use: For use by licensed veterinarians and veterinary technicians in clinical and post-discharge settings to apply controlled sub-atmospheric pressure to open, contaminated, or free-skin-grafted distal-extremity wounds in dogs and horses, as an adjunct to standard wound management.

Who pays

There is no third link in this chain that a US medtech business case usually has: no payer. That single structural fact is what everything below has to be read against.

• Writes the cheque: the dog's or horse's owner, in cash, at the point of service through the treating practice. There is no third-party payer code — HCPCS or otherwise — for veterinary NPWT [claim 11: unconfirmed]. Pet insurance, where an owner carries it, reimburses the owner after the fact rather than paying the practice or the manufacturer up front, and covers under 5% of owned dogs [claim 12: unconfirmed] — the file's own read is that insurance is not a material demand driver at this price point.
• Out of which budget line: at the practice, this is a per-case dressing/supply purchase marked up and billed through to the owner on the surgical or treatment invoice — not a capital-equipment purchase against a rental fleet, and not a claim against a payer fee schedule, because none exists to bill against [claim 11: unconfirmed].
• Against which comparator: the human single-use canister-free device (Smith & Nephew PICO) that veterinarians already buy off-label for this exact use, at a unit price the file claims — but does not establish — to be comparable to the proposed unit [claim 25: unconfirmed]; and the conventional canistered analog (3M/KCI V.A.C.) named in the candidate's own frontmatter as the wider incumbent.
• Stops buying instead: at a practice already using off-label human PICO or a canistered system, a purpose-built unit would substitute for that off-label purchase — but only if the practice actually switches, and the file records that as an unresolved behavioral claim with no primary research behind it, not a house view [claim 19: unconfirmed]. At a practice not currently offering any form of NPWT, this is additive spend rather than substitution, and the file does not establish what share of practices that describes.

The chain's weakest link is the one everything else depends on. Every dollar in the money model below is one owner's decision to pay cash, once, for one case — not a reimbursed device with a payer setting a floor price. Nothing in this case rests on a coverage or payment decision, because there is no coverage or payment decision to model.

The money model

Decomposed, not asserted. Every line resolves to a copied claim or a declared assumption.

Read the largest number first. The composite revenue pool is arithmetic over three Generator-estimated ranges, none with a primary source, multiplied together — and it is canine only. Whatever the equine segment adds is not established anywhere in the file ([assumption A1]).

The two connectors this repo builds specifically to refuse a business case's usual load-bearing claims were run against this file's own decomposition, and the verdict goes on the page rather than being routed around:

• python3 -m connectors market "Annual US caseload of canine degloving, shearing and distal-limb wounds warranting NPWT or free skin grafting, multiplied by net selling price per unit and by obtainable practice share, yields the addressable US canine revenue pool for this product" → unverifiable — "Market-size claim (...) has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed report and edits the claim by hand."
• python3 -m connectors adoption "A veterinary practice that currently buys off-label human PICO units for canine and equine distal-limb wounds would switch its purchasing to a purpose-built veterinary-labeled canister-free NPWT unit at a comparable or higher price" → unverifiable — "Adoption/preference claim (...) asserts what clinicians, payers, or patients would do. No free, authoritative, machine-queryable source answers that — it needs primary research (interviews, survey, published preference study). Stays unconfirmed permanently unless a human attaches real research and edits the claim by hand. Do NOT substitute a model's own estimate of stakeholder behaviour: a synthetic stakeholder opinion is a fabricated claim."

The connectors' own suggested rescope route is closed here too, and the candidate file already establishes why. procedures is Medicare fee-for-service and covers no animal procedures under any code — confirmed again on this build (python3 -m connectors procedures "NPWT" → unconfirmed, "No local cache at data/medicare_procedure_volumes.csv", a missing-data reason sitting on top of the deeper structural one: no CMS dataset ever reaches an animal). hcpcs, payment, and coverage each require a specific code as input, and no code exists for veterinary NPWT to query [claim 11: unconfirmed] — inventing one to query would manufacture a null result rather than test anything, so none was run.

Path to first revenue

• First dollar comes from: an ACVS-affiliated specialty/referral hospital or an equine surgical practice buying the unit for a case — the obtainable segment the file's own share estimate is drawn from [claim 15: unconfirmed].
• What must exist first, each attributed:
  • A functioning fur-compatible adhesive drape holding seal at approximately -80 mmHg for at least 72 hours of normal ambulation [claim 28: unconfirmed], on a limb-conforming interface that survives normal animal behaviour and bandage-over-dressing practice without loss of seal [claim 29: unconfirmed], with adhesive/drape contact producing irritation below the level that hampers negative pressure [claim 30: unconfirmed].
  • Sterile packaging and dressing tooling validated to a standard that supports the labelled claims, in the absence of any premarket review [claim 31: unconfirmed] — the "absence of premarket review" half of that itself rests on claim 1, still unconfirmed as an attribution to FDA CPG Sec. 655.100 [claim 1: unconfirmed]; what is actually verified is the narrower registration-and-listing exemption [claim 2: verified], not the premarket slice.
  • A veterinary technician able to apply the drape and achieve a reliable working seal in ordinary practice conditions, without specialist training [claim 23: unconfirmed].
  • A distributor relationship that actually lists the SKU [claim 26: unconfirmed].
  • No live, enforceable patent blocking the canister-free/superabsorbent format or the dressing-interface chemistry — unsearched rather than cleared [claim 7: unconfirmed].
• Calendar to first dollar: not established anywhere in the file as a specific figure [assumption A2].
• Capital to first dollar: low single-digit millions [claim 18: unconfirmed].

Routes

Four, laid out and not ranked. Choosing a commercial strategy is a Tier 3 act — the same class of decision as choosing what to shortlist — so this section presents options and stops.

Route A — Sell hardware into the existing veterinary distribution channel, cash-pay, full stated indication

The model the candidate file already describes: a device company selling units through Covetrus, Patterson, or Midwest Veterinary Supply to ACVS-affiliated specialty/referral and equine surgical practices, who bill the owner directly [claim 15: unconfirmed].

• Requires: a functioning drape and limb interface [claim 28: unconfirmed], [claim 29: unconfirmed]; sterile packaging validated absent premarket review [claim 31: unconfirmed]; a distributor actually listing the SKU [claim 26: unconfirmed]; and technicians able to apply it reliably [claim 23: unconfirmed].
• Costs: low single-digit millions to reach first revenue [claim 18: unconfirmed], plus a distributor channel-build cost and calendar not established anywhere in the file [assumption A6], and a calendar to first dollar likewise not established [assumption A2].
• Killed by: gross margin at the $180-$320 price does not survive dressing cost of goods and the distributor's own margin stack [claim 27: unconfirmed] resolving false — or the distributor simply keeps stocking off-label human PICO, which practices already buy at a comparable price [claim 25: unconfirmed], and never lists a veterinary-labeled SKU at all [claim 26: unconfirmed] resolving false. If the channel cannot make money carrying it, there is no other buyer in this route.

Route B — License the fur-compatible drape/interface module into an existing NPWT platform or veterinary rental vendor

Ship the differentiator, not a standalone product: an OEM drape-and-interface module into an existing canister-free NPWT platform or into one of the veterinary NPWT rental vendors already operating in this market.

• Requires: patentable claim scope on the drape/interface — the file's stated moat, unfiled and unsearched [claim 16: unconfirmed]; an FTO position on the live canister-free / superabsorbent patent family, itself unsearched because no patent number has been identified to query [claim 7: unconfirmed]; and a partner willing to integrate a third-party module rather than build its own [assumption A3].
• Costs: no distributor channel build of its own; a regulatory scoping opinion and bench validation spend against the same drape-performance claims as Route A [claim 28: unconfirmed], [claim 29: unconfirmed]. Revenue here is a royalty or transfer price, not a device price, so the capital estimate scoped to a standalone product [claim 18: unconfirmed] does not transfer directly [assumption A3].
• Killed by: a prior-art/FTO search finding the drape chemistry and limb interface have no available claim scope, or are blocked by existing live NPWT dressing-interface patents [claim 7: unconfirmed] resolving false — there is nothing defensible to license.

Route C — Own the service: a direct-to-practice rental/application model

Bypass a hardware sale: run the device as a rental/application service, following the precedent of the veterinary NPWT rental vendors already operating in this market, billing the practice or owner per treatment episode rather than selling a unit.

• Requires: technicians able to apply and retrieve the device reliably [claim 23: unconfirmed]; owners willing to pay several hundred dollars out of pocket for the therapy [claim 21: unconfirmed] at a fee comparable to or above what they would pay for an off-label PICO rental today [claim 25: unconfirmed]; and a service-delivery cost structure that leaves margin at the achievable fee [assumption A4].
• Costs: the same device-development baseline as claim 18 [claim 18: unconfirmed] to build a working unit, plus per-episode delivery, setup, training, and retrieval labor cost, which is not priced anywhere in the file [assumption A4].
• Killed by: practices and owners simply keep buying or renting off-label human PICO at a comparable price [claim 25: unconfirmed] and see no reason to switch service providers [claim 19: unconfirmed] resolving false — the file records this switching behavior as a stated belief with no primary research behind it, and this route depends on it directly.

Route D — Narrow the initial target to canine free-skin-graft cases at specialty referral centers

Defer equine and general cutaneous canine wounds; launch into the one sub-indication where the published veterinary literature is directionally positive rather than mixed or negative.

• Requires: the free-skin-graft case series, whose bibliographic existence is verified [claim 8: verified] — note that tag covers existence only, not the finding itself — reporting 100% graft survival and only a minor tubing complication when read at abstract depth [claim 35: unconfirmed], set against the general cutaneous-wound finding that a comparable canister-free device performed worse than control on every measured endpoint [claim 9: unconfirmed], and the equine distal-limb finding that NPWT gave significantly less early wound retraction than calcium alginate at this candidate's exact anatomical site [claim 20: unconfirmed].
• Costs: the same drape/interface and packaging-validation baseline as Route A [claim 28: unconfirmed], [claim 31: unconfirmed], with no claim in the file establishing that a narrower indication requires a smaller or shorter case series than the full-indication estimate assumes [assumption A5].
• Killed by: a full read of the AJVR study or the equine distal-limb study showing the negative-direction finding extends to grafted distal-limb wounds specifically, and not only to the general cutaneous and calcium-alginate-comparator populations actually studied [claim 9: unconfirmed], [claim 20: unconfirmed] resolving unfavorably — the wedge indication would then carry the same evidence problem as the general one.

Assumption register

Every assumption cited above, with what would settle it and who could run it. These are written back to the candidate as unverified claims 40-45 — an assumption that lives only in a business case is invisible to the Verifier.

Where this case outruns the file

Every figure with no claim behind it, gathered as work items.

• The composite canine revenue pool (~$1.1M-$7.7M/yr, ~$3.4M/yr at midpoints) — arithmetic over three unconfirmed Generator-estimated claims (13, 14, 15). No claim in the file asserts this composite, and market returns unverifiable on it permanently.
• The equine segment's contribution to that pool (A1) — not established at all; the file's three TAM components are stated as canine components only, with no equine equivalent anywhere in the file.
• Calendar to first dollar (A2) — the file gives a capital figure (claim 18) and no calendar figure of its own.
• Device- and route-level unit economics beyond the qualitative statement in claim 27 — no bill-of-materials cost, no distributor margin percentage, and no fleet or per-unit price anywhere in the file.
• Route B's licensing/royalty economics (A3) — nothing in the file addresses whether any platform maker or rental vendor would pay for this module, at what rate, or on what terms.
• Route C's per-episode service economics (A4) — nothing in the file prices technician labor, reprocessing, or retrieval cost for a rental/service model.
• Route D's narrower-indication cost saving (A5) — the file's capital estimate is scoped to the full stated indication, and nothing in the file prices a narrower one.
• Distribution channel-build cost and calendar (A6) — claim 26 addresses only whether a distributor would carry the SKU, not what building that relationship costs or how long it takes.